Press Releases

Tel Aviv, Israel— November 13, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the Company’s CGuard™ Embolic Prevention System will be featured in several podium presentations during the upcoming VEITHsymposium, which is… Read More

Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System   On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET   Tel Aviv, Israel— November 6, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of… Read More

Conference Call Scheduled for 8am Eastern Time Tel Aviv, Israel— October 30, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, November 6,… Read More

Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis Tel Aviv, Israel— September 27, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that… Read More

Commercial Launch to Occur Immediately   Tel Aviv, Israel— September 24, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard™ Embolic Prevention System (EPS) has been granted regulatory approval by… Read More

Patents further strengthen intellectual property surrounding Company’s lead commercial product, CGuard™ EPS  InspireMD remains on track to submit an Investigational Device Exception (IDE) with FDA in mid-2019 Tel Aviv, Israel— September 17, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the… Read More

Tel Aviv, Israel— September 4, 2018 – InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be presenting at the H.C. Wainwright 20th Annual Global Investment Conference (previously known as the Rodman and Renshaw conference). … Read More

Tel Aviv, Israel— August 6, 2018 – InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter ending June 30, 2018. Second Quarter 2018 highlights: Revenues in Q2 of $1.0 million for 2018… Read More

Tel Aviv – July 31, 2018 – InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it will host a conference call on Tuesday, August 7th at 8:00 a.m. Eastern Time to discuss the company’s financial… Read More

Tel Aviv, Israel— July 23, 2018 – InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it has established its first two Centers of Excellence (COE) at leading hospitals in Europe. The first COE is… Read More